This is therefore a contrasting of the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation in Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Sutro Biopharma Inc. (NASDAQ:STRO). The two are both Biotechnology companies that compete with one another.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Alnylam Pharmaceuticals Inc.||79||86.76||N/A||-7.88||0.00|
|Sutro Biopharma Inc.||11||5.37||N/A||-1.66||0.00|
Table 1 shows the top-line revenue, earnings per share and valuation for Alnylam Pharmaceuticals Inc. and Sutro Biopharma Inc.
Table 2 has Alnylam Pharmaceuticals Inc. and Sutro Biopharma Inc.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alnylam Pharmaceuticals Inc.||0.00%||-53.9%||-45.5%|
|Sutro Biopharma Inc.||0.00%||0%||0%|
The Current Ratio of Alnylam Pharmaceuticals Inc. is 9.3 while its Quick Ratio stands at 9.1. The Current Ratio of rival Sutro Biopharma Inc. is 5.7 and its Quick Ratio is has 5.7. Alnylam Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Sutro Biopharma Inc.
In next table is given Alnylam Pharmaceuticals Inc. and Sutro Biopharma Inc.’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Alnylam Pharmaceuticals Inc.||0||1||9||2.90|
|Sutro Biopharma Inc.||0||0||0||0.00|
Alnylam Pharmaceuticals Inc. has a consensus target price of $126.73, and a 60.66% upside potential.
Institutional and Insider Ownership
Alnylam Pharmaceuticals Inc. and Sutro Biopharma Inc. has shares owned by institutional investors as follows: 89.2% and 73.1%. Insiders owned roughly 0.5% of Alnylam Pharmaceuticals Inc.’s shares. Comparatively, insiders own roughly 21.23% of Sutro Biopharma Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Alnylam Pharmaceuticals Inc.||1.45%||7.75%||-6.55%||-5.03%||-19.85%||6.42%|
|Sutro Biopharma Inc.||1.9%||-4.09%||13.27%||5.52%||0%||24.94%|
For the past year Alnylam Pharmaceuticals Inc.’s stock price has smaller growth than Sutro Biopharma Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.